Oct. 30, 2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

A drug used to treat glaucoma may protect against tau protein buildup in the brain, a key marker of dementias such as ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

While Parkinson’s disease (PD ... on neuroprotective and disease-modifying agents, reflecting the field’s commitment to ...

Nilotinib, a drug approved by the US Food and Drug Administration ... and the International Parkinson and Movement Disorder ...

Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming ...

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be ...

Research Triangle Park, North Carolina Saturday, November 9, 2024, 13:00 Hrs [IST] ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part ...

Out-of-pocket costs for branded drugs to treat multiple sclerosis (MS), Alzheimer's, and Parkinson's disease rose from 2012 ...